Leidos slips 5% as investors weigh defense health EHR shift and recent analyst caution

Leidos Holdings (LDOS) is down 5.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears tied to renewed concerns about Leidos’ role in the Military Health System’s electronic health record ecosystem after the Defense Health Agency outlined a plan to move away from the current lead-integrator model. The move also comes after a high-profile analyst downgrade earlier in June that highlighted slower organic-growth expectations and questioned parts of the company’s health-related business, potentially adding to selling pressure.

Details:

The Defense Health Agency outlined an approach to contract directly with Oracle Health and several other underlying technology vendors and to take on integration responsibilities internally, reducing reliance on the current integrator setup.

The agency’s transition plan referenced moving certain components away from Leidos’ management by end of July 2026, with additional transitions targeted for November 2026 and into 2027.

Earlier this month, an analyst downgrade to Hold included a large price-target cut, citing limited organic growth prospects and concerns around the company’s health business.

Leidos’ most recent quarterly update reiterated stronger profitability and raised full-year fiscal 2026 guidance, suggesting the selloff is more about forward contract/mix risk than a newly reported earnings miss.

Sources:

Washington Technology, Leidos Investor Relations, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LDOS Insider Trading Activity

$LDOS insiders have traded $LDOS stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $LDOS stock by insiders over the last 6 months:

ELIZABETH A PORTER (Sector President) has made 0 purchases and 5 sales selling 8,000 shares for an estimated $1,437,320.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$LDOS Hedge Fund Activity

We have seen 419 institutional investors add shares of $LDOS stock to their portfolio, and 511 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DIAMANT ASSET MANAGEMENT, INC. added 4,131,706 shares (+16475.4%) to their portfolio in Q1 2026, for an estimated $642,562,917
FIRST TRUST ADVISORS LP removed 1,152,978 shares (-41.9%) from their portfolio in Q1 2026, for an estimated $179,311,138
SG AMERICAS SECURITIES, LLC added 997,807 shares (+998.6%) to their portfolio in Q1 2026, for an estimated $155,178,944
FMR LLC removed 949,765 shares (-30.2%) from their portfolio in Q1 2026, for an estimated $147,707,452
BLACKROCK, INC. removed 838,482 shares (-8.1%) from their portfolio in Q1 2026, for an estimated $130,400,720
MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. added 565,138 shares (+45.5%) to their portfolio in Q1 2026, for an estimated $87,890,261
PACER ADVISORS, INC. removed 504,599 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $91,029,659

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$LDOS Government Contracts

We have seen $8,523,463,883 of award payments to $LDOS over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

FY26 FUNDING MEDICAL DISABILITY EXAMINATIONS: $754,312,385
FY26 FUNDING MEDICAL DISABILITY EXAMINATIONS: $392,676,748
FY25 Q3 EXAMS R2: $382,099,483
FY26 FUNDING MEDICAL DISABILITY EXAMINATIONS: $348,691,285
MODIFICATION TO UPDATE REVISE PWS AND ATTACHMENT AR.: $335,920,664

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$LDOS Analyst Ratings

Wall Street analysts have issued reports on $LDOS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citigroup issued a "Buy" rating on 01/13/2026

To track analyst ratings and price targets for $LDOS, check out Quiver Quantitative's $LDOS forecast page.

$LDOS Price Targets

Multiple analysts have issued price targets for $LDOS recently. We have seen 9 analysts offer price targets for $LDOS in the last 6 months, with a median target of $193.0.

Here are some recent targets:

Sheila Kahyaoglu from Jefferies set a target price of $140.0 on 06/03/2026
John Godyn from Citigroup set a target price of $178.0 on 05/07/2026
Ken Herbert from RBC Capital set a target price of $180.0 on 05/06/2026
Jonathan Siegmann from Stifel set a target price of $193.0 on 05/06/2026
Mariana Perez from B of A Securities set a target price of $200.0 on 04/21/2026
Tobey Sommer from Truist Securities set a target price of $195.0 on 04/20/2026
David Strauss from Wells Fargo set a target price of $165.0 on 04/01/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.